Do analysts rate AQB or ATOS?

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 728.24%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is AQB or ATOS more profitable?

Atossa Genetics' return on equity of -94.57% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets AquaBounty Technologies N/A -147.07% -28.73% Atossa Genetics N/A -94.57% -78.80%

Do analysts prefer AQB or NCEL?

NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 618.75%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, AQB or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than AquaBounty Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AquaBounty Technologies $2.47M 2.64 -$18.49M -$1.19 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is AQB or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets AquaBounty Technologies N/A -147.07% -28.73% NLS Pharmaceutics N/A N/A N/A

Do analysts recommend AQB or HOWL?

Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 856.63%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Is AQB or HOWL more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets AquaBounty Technologies N/A -147.07% -28.73% Werewolf Therapeutics N/A -166.99% -59.88%

Is NRSN or AQB more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A AquaBounty Technologies N/A -147.07% -28.73%

Do analysts rate AQB or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

AquaBounty Technologies (AQB) Competitors

$1.26 +0.10 (+8.12%)

As of 01:21 PM Eastern

Compare

AQB vs. ATOS, NCEL, HOWL, NRSN, and PLUR

Should you buy AquaBounty Technologies stock or one of its competitors? MarketBeat compares AquaBounty Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AquaBounty Technologies include Atossa Genetics (ATOS), NLS Pharmaceutics (NCEL), Werewolf Therapeutics (HOWL), NeuroSense Therapeutics (NRSN), and Pluri (PLUR). These companies are all part of the "biotechnology" industry.

How does AquaBounty Technologies compare to Atossa Genetics?

AquaBounty Technologies (NASDAQ:AQB) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 728.24%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Atossa Genetics had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 2 mentions for Atossa Genetics and 1 mentions for AquaBounty Technologies. Atossa Genetics' average media sentiment score of 1.50 beat AquaBounty Technologies' score of 0.69 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
AquaBounty Technologies	Positive
Atossa Genetics	Very Positive

AquaBounty Technologies has higher revenue and earnings than Atossa Genetics. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.64	-$18.49M	-$1.19	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Atossa Genetics' return on equity of -94.57% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Atossa Genetics	N/A	-94.57%	-78.80%

AquaBounty Technologies has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Atossa Genetics beats AquaBounty Technologies on 9 of the 14 factors compared between the two stocks.

How does AquaBounty Technologies compare to NLS Pharmaceutics?

AquaBounty Technologies (NASDAQ:AQB) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 618.75%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics' return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
NLS Pharmaceutics	N/A	N/A	N/A

NLS Pharmaceutics has lower revenue, but higher earnings than AquaBounty Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.64	-$18.49M	-$1.19	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

AquaBounty Technologies has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

8.9% of AquaBounty Technologies shares are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, AquaBounty Technologies had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for AquaBounty Technologies and 0 mentions for NLS Pharmaceutics. AquaBounty Technologies' average media sentiment score of 0.69 beat NLS Pharmaceutics' score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
AquaBounty Technologies	Positive
NLS Pharmaceutics	Neutral

Summary

NLS Pharmaceutics beats AquaBounty Technologies on 7 of the 12 factors compared between the two stocks.

How does AquaBounty Technologies compare to Werewolf Therapeutics?

AquaBounty Technologies (NASDAQ:AQB) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

AquaBounty Technologies' return on equity of -147.07% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

AquaBounty Technologies has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AquaBounty Technologies and AquaBounty Technologies both had 1 articles in the media. AquaBounty Technologies' average media sentiment score of 0.69 beat Werewolf Therapeutics' score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
AquaBounty Technologies	Positive
Werewolf Therapeutics	Neutral

AquaBounty Technologies has higher revenue and earnings than Werewolf Therapeutics. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.64	-$18.49M	-$1.19	N/A
Werewolf Therapeutics	$1.88M	10.13	-$60.82M	-$0.76	N/A

Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 856.63%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Werewolf Therapeutics beats AquaBounty Technologies on 8 of the 14 factors compared between the two stocks.

How does AquaBounty Technologies compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

NeuroSense Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 1,638.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe NeuroSense Therapeutics is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeuroSense Therapeutics' return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
AquaBounty Technologies	N/A	-147.07%	-28.73%

NeuroSense Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 1 articles in the media. AquaBounty Technologies' average media sentiment score of 0.69 beat NeuroSense Therapeutics' score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
NeuroSense Therapeutics	Neutral
AquaBounty Technologies	Positive

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NeuroSense Therapeutics has higher earnings, but lower revenue than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
AquaBounty Technologies	$2.47M	2.64	-$18.49M	-$1.19	N/A

Summary

NeuroSense Therapeutics beats AquaBounty Technologies on 11 of the 14 factors compared between the two stocks.

How does AquaBounty Technologies compare to Pluri?

AquaBounty Technologies (NASDAQ:AQB) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

AquaBounty Technologies has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Pluri	-2,162.08%	N/A	-106.59%

AquaBounty Technologies has higher revenue and earnings than Pluri. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.64	-$18.49M	-$1.19	N/A
Pluri	$1.34M	14.66	-$22.58M	-$4.53	N/A

In the previous week, AquaBounty Technologies had 1 more articles in the media than Pluri. MarketBeat recorded 1 mentions for AquaBounty Technologies and 0 mentions for Pluri. AquaBounty Technologies' average media sentiment score of 0.69 beat Pluri's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
AquaBounty Technologies	Positive
Pluri	Neutral

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by insiders. Comparatively, 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AquaBounty Technologies has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Pluri has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

AquaBounty Technologies beats Pluri on 8 of the 13 factors compared between the two stocks.

Get AquaBounty Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQB vs. The Competition

Export

Metric	AquaBounty Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.52M	$3.72B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.06	9.08	269.97	24.82
Price / Sales	2.64	1,268.38	650.66	108.09
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	-2.58	17.65	11.26	6.44
Net Income	-$18.49M	-$13.25M	$3.45B	$347.27M
7 Day Performance	37.56%	5.33%	3.62%	2.55%
1 Month Performance	29.08%	-1.83%	-0.56%	-1.02%
1 Year Performance	69.10%	61.05%	77.38%	23.33%

AquaBounty Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQB AquaBounty Technologies	0.5142 of 5 stars	$1.27 +8.1%	N/A	+56.4%	$6.52M	$2.47M	N/A	100	Earnings Report Gap Up High Trading Volume
ATOS Atossa Genetics	2.5803 of 5 stars	$2.31 +6.5%	$20.33 +780.2%	-80.0%	$18.69M	N/A	N/A	8	Positive News Earnings Report Gap Down
NCEL NLS Pharmaceutics	1.8284 of 5 stars	$3.45 +0.9%	$23.00 +566.7%	-84.5%	$18.28M	N/A	N/A	6	Gap Down
HOWL Werewolf Therapeutics	2.617 of 5 stars	$0.41 +12.8%	$3.75 +804.5%	-66.1%	$17.86M	$1.88M	N/A	40	Upcoming Earnings
NRSN NeuroSense Therapeutics	3.0247 of 5 stars	$0.52 +11.3%	$8.50 +1,534.9%	-60.3%	$17.64M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AquaBounty Technologies (AQB) Competitors

AQB vs. ATOS, NCEL, HOWL, NRSN, and PLUR

How does AquaBounty Technologies compare to Atossa Genetics?

Summary

How does AquaBounty Technologies compare to NLS Pharmaceutics?

Summary

How does AquaBounty Technologies compare to Werewolf Therapeutics?

Summary

How does AquaBounty Technologies compare to NeuroSense Therapeutics?

Summary

How does AquaBounty Technologies compare to Pluri?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB vs. The Competition

AquaBounty Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AquaBounty Technologies (AQB) Competitors

AQB vs. ATOS, NCEL, HOWL, NRSN, and PLUR

How does AquaBounty Technologies compare to Atossa Genetics?

Do analysts rate AQB or ATOS?

Does the media prefer AQB or ATOS?

Which has stronger earnings and valuation, AQB or ATOS?

Is AQB or ATOS more profitable?

Which has more risk and volatility, AQB or ATOS?

Do insiders and institutionals have more ownership in AQB or ATOS?

Summary

How does AquaBounty Technologies compare to NLS Pharmaceutics?

Do analysts prefer AQB or NCEL?

Is AQB or NCEL more profitable?

Which has higher earnings & valuation, AQB or NCEL?

Which has more risk & volatility, AQB or NCEL?

Do insiders and institutionals hold more shares of AQB or NCEL?

Does the media refer more to AQB or NCEL?

Summary

How does AquaBounty Technologies compare to Werewolf Therapeutics?

Is AQB or HOWL more profitable?

Which has more volatility and risk, AQB or HOWL?

Do insiders & institutionals have more ownership in AQB or HOWL?

Does the media refer more to AQB or HOWL?

Which has preferable earnings & valuation, AQB or HOWL?

Do analysts recommend AQB or HOWL?

Summary

How does AquaBounty Technologies compare to NeuroSense Therapeutics?

Do analysts rate NRSN or AQB?

Is NRSN or AQB more profitable?

Which has more volatility & risk, NRSN or AQB?

Does the media prefer NRSN or AQB?

Do insiders & institutionals hold more shares of NRSN or AQB?

Which has stronger valuation & earnings, NRSN or AQB?

Summary

How does AquaBounty Technologies compare to Pluri?

Is AQB or PLUR more profitable?

Which has stronger earnings & valuation, AQB or PLUR?

Does the media refer more to AQB or PLUR?

Do institutionals & insiders hold more shares of AQB or PLUR?

Which has more risk & volatility, AQB or PLUR?

Do analysts rate AQB or PLUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB vs. The Competition

AquaBounty Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools